Intellia Therapeutics (NTLA) News Today $7.30 +0.64 (+9.61%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$6.88 -0.42 (-5.68%) As of 05:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?April 3 at 12:18 AM | finance.yahoo.comNTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 2 at 4:00 PM | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Sets New 1-Year Low - What's Next?Intellia Therapeutics (NASDAQ:NTLA) Reaches New 52-Week Low - Should You Sell?April 2 at 10:56 AM | marketbeat.comNTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 2 at 10:16 AM | prnewswire.comIs Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?April 2 at 7:25 AM | msn.comROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLAApril 1 at 2:06 PM | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Trading Down 9.6% - Should You Sell?Intellia Therapeutics (NASDAQ:NTLA) Trading Down 9.6% - What's Next?April 1 at 2:00 PM | marketbeat.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLAApril 1 at 1:43 PM | globenewswire.comShareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLAApril 1 at 5:45 AM | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLAMarch 31 at 1:08 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLAMarch 31 at 12:43 PM | prnewswire.comContact The Gross Law Firm by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc.(NTLA)March 31 at 5:45 AM | prnewswire.comIQ EQ FUND MANAGEMENT IRELAND Ltd Has $637,000 Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 137.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,657 shares of the companMarch 30, 2025 | marketbeat.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. ...March 29, 2025 | gurufocus.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLAMarch 29, 2025 | globenewswire.comNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud LawsuitMarch 29, 2025 | prnewswire.comQ2 Earnings Estimate for NTLA Issued By William BlairIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at William Blair issued their Q2 2026 earnings estimates for shares of Intellia Therapeutics in a research report issued to clients and investors on Wednesday, March 26th. William Blair analyst M. Minter expects that the company wMarch 29, 2025 | marketbeat.comWhat is William Blair's Estimate for NTLA Q2 Earnings?March 29, 2025 | americanbankingnews.comQ1 Earnings Estimate for NTLA Issued By William BlairIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings estimates for Intellia Therapeutics in a report released on Wednesday, March 26th. William Blair analyst M. Minter expects that the company will earn ($1.12) per share forMarch 28, 2025 | marketbeat.comLevi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLAMarch 28, 2025 | prnewswire.comEntryPoint Capital LLC Acquires New Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)EntryPoint Capital LLC bought a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 32,425 shares of the company's stock, valued at approximately $378,000.March 28, 2025 | marketbeat.comEquities Analysts Offer Predictions for NTLA Q1 EarningsMarch 28, 2025 | americanbankingnews.comIntellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.March 27, 2025 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Reaches New 52-Week Low - What's Next?Intellia Therapeutics (NASDAQ:NTLA) Hits New 12-Month Low - Should You Sell?March 27, 2025 | marketbeat.comLevi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming DeadlineMarch 27, 2025 | globenewswire.comThe Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLAMarch 27, 2025 | prnewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLAMarch 26, 2025 | globenewswire.comIntellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLAMarch 26, 2025 | globenewswire.comNTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 26, 2025 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Down 6% - Here's What HappenedIntellia Therapeutics (NASDAQ:NTLA) Trading Down 6% - Time to Sell?March 26, 2025 | marketbeat.comIntellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with CardiomyopathyMarch 26, 2025 | globenewswire.comRaymond James Financial Inc. Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Raymond James Financial Inc. purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 411,077 shares of the company's stock, valued at approximately $4,793,000. RaymondMarch 26, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLAMarch 25, 2025 | prnewswire.comNTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMarch 25, 2025 | prnewswire.comNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud LawsuitMarch 24, 2025 | prnewswire.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia TherapeuticsMarch 24, 2025 | tmcnet.comClass Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors – Contact Levi & KorsinskyMarch 24, 2025 | globenewswire.comLost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law FirmMarch 24, 2025 | prnewswire.comResearch Analysts Offer Predictions for NTLA FY2027 EarningsIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a report released on Thursday, March 20th. Zacks Research analyst R. Department expects that the company wMarch 24, 2025 | marketbeat.comROSEN, A RANKED AND LEADING FIRM, Encourages Intellia Therapeutics, Inc. ...March 23, 2025 | gurufocus.comROSEN, A RANKED AND LEADING FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLAMarch 23, 2025 | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia TherapeuticsMarch 23, 2025 | globenewswire.comCharles Schwab Investment Management Inc. Reduces Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Charles Schwab Investment Management Inc. lessened its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 787,490 shares of the company's stock after sellinMarch 23, 2025 | marketbeat.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLAMarch 22, 2025 | investing.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of "Moderate Buy" by BrokeragesShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nineteen brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold ratinMarch 22, 2025 | marketbeat.comApril 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLAMarch 21, 2025 | globenewswire.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtMarch 21, 2025 | fool.comNTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMarch 21, 2025 | prnewswire.comContrarius Group Holdings Ltd Invests $11.80 Million in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Contrarius Group Holdings Ltd bought a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,011,863 shares of the comMarch 21, 2025 | marketbeat.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLAMarch 21, 2025 | prnewswire.com Remove Ads Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.220.53▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼3210▲NTLA Articles Average Week Remove Ads Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Metsera News Immunovant News Alvotech News MorphoSys News Apellis Pharmaceuticals News ACADIA Pharmaceuticals News Viking Therapeutics News HUTCHMED News Amneal Pharmaceuticals News ImmunityBio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NTLA Stock Free NTLA Stock Alerts